Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Noxopharm Ltd. ( (AU:NOX) ) is now available.
Noxopharm Limited announced the successful completion of the fourth and final single-dose cohort in the HERACLES clinical trial for SOF-SKN™, a novel drug candidate for autoimmune diseases. The trial, conducted in Australia, confirmed the safety and tolerability of SOF-SKN at its highest dose, marking a significant milestone in its development. This advancement positions Noxopharm to further explore SOF-SKN’s potential applications in treating autoimmune-related skin diseases and other conditions linked to immune system dysregulation. The global market for cutaneous lupus erythematosus, one of the target diseases, is valued at over US$3.3 billion and is expected to grow, highlighting the commercial potential of Noxopharm’s innovations.
More about Noxopharm Ltd.
Noxopharm Limited is a clinical-stage Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company leverages its proprietary Sofra™ and Chroma™ technology platforms to create a pipeline of new drugs targeting inflammation, autoimmunity, mRNA drug enhancement, and oncology. Noxopharm collaborates with leading researchers to enhance its drug development capabilities.
Average Trading Volume: 297,365
Technical Sentiment Signal: Buy
Current Market Cap: A$30.68M
See more data about NOX stock on TipRanks’ Stock Analysis page.